Department of Gastroenterology, First Affiliated Hospital of Guangxi Medical University, Shuangyong Road 6, Nanning, 530021, Guangxi, China.
Department of Gastroenterology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, 541002, China.
BMC Gastroenterol. 2022 May 11;22(1):232. doi: 10.1186/s12876-022-02313-x.
The detection rate of methylated Septin9 (mSEPT9) in colorectal cancer (CRC) is varied greatly across the studies. This study aimed to evaluate the diagnostic ability of mSEPT9 in CRC, and compare the diagnostic efficacy with fecal immunochemical test (FIT).
326 subjects from four centers were prospectively recruited, including 179 CRC and 147 non-CRC subjects. The plasma was collected for mSEPT9 and CEA, AFP, CA125, CA153 and CA199 test, and fecal samples for FIT tests. Sensitivity, specificity and area under the curve (AUC) of receiver operating characteristic curve were calculated to evaluate the diagnostic value of each biomarker.
The positive rate in mSEPT9 and FIT, and the level of CEA, CA125 and CA199 were significantly higher in CRC compared with non-CRC subjects. The mSEPT9 positive rate was not associated with TNM stage and tumor stage. The sensitivity, specificity and AUC of mSEPT9 in diagnostic CRC were 0.77, 0.88 and 0.82, respectively, while the value in FIT was 0.88, 0.80 and 0.83, respectively. mSEPT9 and FIT have higher AUC value than that of CEA, CA125 and CA199. Combination of both mSEPT9 and FIT positive increased sensitivity and AUC to 0.98 and 0.83, respectively, but the specificity was declined. mSEPT9 has a slightly low sensitivity in diagnosis of colon cancer (0.87) compared with rectal cancer (0.93).
mSEPT9 demonstrated moderate diagnostic value in CRC detection, which was similar to the FIT but superior to the CEA, CA125 and CA199. Combination of mSEPT9 and FIT further improved diagnostic sensitivity in CRC.
ChiCTR2000038319.
甲基化 Septin9（mSEPT9）在结直肠癌（CRC）中的检出率在不同研究中差异很大。本研究旨在评估 mSEPT9 在 CRC 中的诊断能力，并与粪便免疫化学检测（FIT）比较诊断效果。
来自四个中心的 326 名患者前瞻性入组，包括 179 例 CRC 和 147 例非 CRC 患者。采集血浆用于 mSEPT9 和 CEA、AFP、CA125、CA153 和 CA199 检测，采集粪便用于 FIT 检测。计算受试者工作特征曲线（ROC）的灵敏度、特异度和曲线下面积（AUC），以评估每个标志物的诊断价值。
CRC 患者的 mSEPT9 和 FIT 阳性率以及 CEA、CA125 和 CA199 水平明显高于非 CRC 患者。mSEPT9 阳性率与 TNM 分期和肿瘤分期无关。mSEPT9 诊断 CRC 的灵敏度、特异度和 AUC 分别为 0.77、0.88 和 0.82，而 FIT 的相应值分别为 0.88、0.80 和 0.83。mSEPT9 和 FIT 的 AUC 值高于 CEA、CA125 和 CA199。mSEPT9 和 FIT 联合阳性可将灵敏度和 AUC 提高至 0.98 和 0.83，但特异性降低。mSEPT9 诊断结肠癌（0.87）的灵敏度略低于直肠癌（0.93）。
mSEPT9 在 CRC 检测中具有中等诊断价值，与 FIT 相似，但优于 CEA、CA125 和 CA199。mSEPT9 和 FIT 联合可进一步提高 CRC 的诊断灵敏度。
ChiCTR2000038319。
